Exelixis has announced it has received FDA approval for Cabometyx to treat patients with hepatocellular carcinoma who previously underwent treatment with Nexavar, according to a press release.
“This new indication for Cabometyx is an important treatment advance for patients with this aggressive form of liver cancer, a community in need of new therapeutic options,” Michael M. Morrissey, PhD, president and CEO of Exelixis, said in the release. “This approval is an important milestone as we continue to explore how Cabometyx may benefit people with difficult-to-treat-cancers beyond renal cell carcinoma.”
Approval was based on results from the CELESTIAL phase 3 trial of Cabometyx (cabozantinib) for patients with HCC who previously received Nexavar (sorafenib, Bayer).
Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.
“We found that untreated HCV infected persons had nearly twice the rate of incident CVD events compared with those who initiated treatment. This was observed for [coronary artery disease (CAD)] events … as well as for stroke and peripheral vascular disease,” Adeel A. Butt, MD, from the Veterans Affairs Pittsburgh Healthcare System, and colleagues wrote. “Our study adds significant new information by assessing older pegylated interferon/ribavirin and newer DAA regimens and their effect on CVD outcomes.”
The study comprised 4,436 patients with chronic hepatitis C who received treatment with pegylated interferon (PEG-IFN) and ribavirin and 12,667 patients who received DAAs. The study also included an equal number of matched controls with HCV who never received any treatment for their infection.
The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.
The license agreement for a generic of Mavyret (glecaprevir/pibrentasvir, AbbVie) was launched at The Liver Meeting 2018 and includes 95 countries and four territories that are low- or middle-income.
Dr. Luis A. Balart, a specialist in diseases of the liver who helped develop a cure for hepatitis C, died of leukemia Monday (Jan. 14) in Boston. He was 70.
Dr. Balart, who had lived in New Orleans since 1961, was in Boston for treatment at Dana-Farber Cancer Institute.
During his four-decade career, which included liver transplantation, Dr. Balart was chief of the gastroenterology departments at LSU and Tulane University medical schools, and he worked at Ochsner Medical Center, Southern Baptist Hospital and Tulane Medical Center
The results of 2 reported case studies of children with chronic hepatitis C infection indicated that viral eradication can be achieved and maintained until full immune recovery throughout allogeneic hematopoietic stem cell transplantation, if the patients receive full courses of direct-acting antivirals (DAAs) immediately before undergoing the procedure, according to a study published in the Journal of Viral Hepatitis.
American Society for Blood and Marrow Transplantation guidelines currently recommend that hematopoietic stem cell transplantation candidates with hepatitis C start and complete DAA therapy prior to undergoing stem cell transplantation. Time constraints and limiting comorbidities, treatments, and conditions can often make this approach unfeasible, but data on antiviral treatment safety and efficacy and the late effects of hepatitis C infection in hematopoietic stem cell transplantation patients are unknown.
This article reports on the cases of 2 children with chronic hepatitis C infection. Patient 1 successfully completed 12 weeks sofosbuvir/ribavirin therapy 6 days prior to undergoing hematopoietic stem cell transplantation for bone marrow failure. Post-transplant, the patient was given cyclosporine A, methotrexate, valaciclovir, and liposomal amphotericin B.
HepVu Releases State-Level Maps Showing Impact of Hepatitis C Epidemic Across the U.S.
Today, HepVu launched new interactive maps visualizing state-level estimates of people living with Hepatitis C across the United States that highlight a concentration of infections in some states most impacted by the opioid epidemic.
Join us at 2PM ET today for a webinar about HepVu’s new data and focus on opioids.
Wednesday, January 16, 2019 Webinar Link Dial-In: 1-701-801-1211 Access Code: 506 325 060
Published in JAMA Network Open, the data reveal an estimated 2.3 million people living with Hepatitis C infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.
Beyond the Map
Read our Q&A on the opioid epidemic’s impact on Hepatitis C with experts Dr. Heather Bradley and Dr. Ron Valdiserri:
Heather Bradley, Ph.D., Assistant Professor of Epidemiology at Georgia State University and HepVu Project Director.
Ron Valdiserri, M.D., MPH, Senior Research Associate and Distinguished Scholar, Johns Hopkins University, Bloomberg School of Public Health, and serves as HepVu Co-Chair.
A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study.
“The prevalence of hepatitis C is higher in prisoners than in the general population, reflecting the criminalization of drug use and the frequent detention of [people who inject drugs (PWIDs)],” Timothy Papaluca, MBBS, FRACP, from the St Vincent’s Hospital and the University of Melbourne, Australia, and colleagues wrote. “This population has not typically been well engaged with specialist care, highlighting the need to develop new models of care for hepatitis C among marginalized, high transmitting populations.”
HepCure Tele-Education Webinar Series Presents:
TREAT FIRST – HCV Treatment and Care at Syringe Access Sites
Pierre-Cedric Crouch, PhD, ANP-BC, ACRN
Director of Nursing
Magenet, San Francisco AIDS Foundation
Senior HCV Coordinator and Harm Reduction Specialist
Syringe Access Service
San Francisco AIDS Foundation
Date: January 15, 2019 Time: 4:30 PM EST
* Pre-registration not required
1. On Tuesday at 4:30PM EST, access the webinar HERE
2. Enter your name and e-mail to log on
660 316 750
Enter your unique participant ID # provided by WebEx when you
About Dr. Crouch
Pierre is the Director of Nursing at Magnet, a community-based arm of the San Francisco AIDS Foundation that delivers sexual health services to gay, bi, and transmasculine communities in the San Francisco Bay Area. He grew up in New Orleans, Louisiana where he obtained his BSN from the Louisiana State University Health Science Center. He had an early passion for HIV care and technology, which lead him to move to San Francisco, where he received his MSN (Nurse Practitioner) and PhD from the University of California, San Francisco. He went on to develop and implement on of the largest nurse-led PrEP Health Program, which has garnered world-wide recognition. He geeks out over technologies that connect clients to their health and the development of RN-delivered community-based care. He leads in Health Care 3.0, which supports nurses practicing to the fullest extent of their license and taking a client-centered approach to remove traditional barriers to accessing health care. He is currently working on expanding anal health services, implementing full point of care STI testing, and developing a nurse-led community-based hepatitis C treatment program.
About Mr. Gray
Pauli Gray has been doing Harm Reduction work with several specialties for 19 years, and Hep C work since 2002. Mr. Gray has done more than 600 Trainings and Speaking events on Hep C, OD Prevention, HIV, Needle Exchange and Harm Reduction, on three continents, from San Francisco to Africa. Besides being the Senior HCV Coordinator and Harm Reduction Specialist at the San Francisco AIDS Foundation for the Syringe Access Services program, Mr. Gray also is a member of the End Hep C Coordinating Committee, Treatment Access, Testing and Linkage Groups, and the Hep C Task Force.
*January 22nd – HepCure/ELF – Dr. Benham Saberi – HCC After DAA Treatment
*February 5th – HepCure/CEI – TBA
February 12th – Andrew Reynolds – An Overview of Non-Injection Drug Use and Hepatitis C
*February 19th – HepCure/ELF- TBA
*Note: all webinars in redrequire pre-registration in order to receive CE credit